Monday, October 22, 2018      
Choose Language  


Drug Name : Xybrone
Drug Category : AntineoPlastics
Pharmacological Category: مهارکننده تولید آندروژن/ Androgen synthesis inhibitor
Brand Name : Xybrone
Drug Forms :

XYBRON® (ABIRATERONE ACETATE) is a CYP17 inhibitor indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer.


Human experience of overdose with ABIRATERONE ACETATE is limited. There is no specific antidote. In the event of an overdose, stop ABIRATERONE ACETATE, undertake general supportive measures, including monitoring for arrhythmias and cardiac failure and assess liver function.

FDA Approval

FDA initially approved abiraterone acetate with prednisone in 2011 for patients with metastatic castration-resistant prostate cancer (CRPC) who had received prior chemotherapy, and expanded the indication in 2012 for patients with metastatic CRPC.